Tanabe Pharma Corporation: Hyperphosphatemia trials

The registry lists 10 Hyperphosphatemia studies with Tanabe Pharma Corporation as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 1Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy SubjectsCompletedNCT01976572Phase 1Results posted
• Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedNCT00772382Phase 3Results posted
• A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedNCT00542815Phase 3Results posted
• A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and DyslipidaemiaCompletedNCT00542386Phase 3Results posted
• A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With HyperphosphatemiaCompletedNCT00506441Phase 3Results posted
• A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With HyperphosphatemiaCompletedNCT00416520Phase 3Results posted
• Safety and Tolerability Study of MCI-196TerminatedNCT01818687Phase 3
• Long-term Extension Study of MCI-196TerminatedNCT01814917Phase 3
• Dose-finding Study of MCI-196TerminatedNCT01814904Phase 3
• A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With HyperphosphatemiaTerminatedNCT00451295Phase 3